Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT127 (TCR-like CAR-T) in MSLN+ Ovarian Cancer
NCT05963100Phase 2Active, not recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Aug 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of KNT-127 in ovarian cancer (4 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoints: Maximum Tolerated Dose up to 2 years and Adverse Events up to 2 years. Started Aug 2023; status: active, not recruiting.
02
Drugs
KNT-127
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05963100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963100.